61363-56-2

Basic information

• Product Name: PYRAN-3,5-DIONE
• Synonyms: PYRAN-3,5-DIONE;Nsc293808;2H-Pyran-3,5(4H,6H)-dione;oxane-3,5-dione
• CAS NO: 61363-56-2
• Molecular Formula: C₅H₆O₃
• Molecular Weight: 114.09934
• Mol File: 61363-56-2.mol
• Article Data: 8

Chemical Properties

• Melting Point: 128-129 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 275.1 °C at 760 mmHg
• Flash Point: 123.4 °C
• Appearance: /
• Density: 1.26 g/cm³
• Vapor Pressure: 0.00776mmHg at 25°C
• Refractive Index: 1.714
• Storage Temp.: 2-8°C
• PKA: 9.24±0.20(Predicted)
• CAS DataBase Reference: PYRAN-3,5-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRAN-3,5-DIONE(61363-56-2)
• EPA Substance Registry System: PYRAN-3,5-DIONE(61363-56-2)

Safety Data

• Hazardous Substances Data: 61363-56-2(Hazardous Substances Data)

Usage

General Description

PYRAN-3,5-DIONE, also known as 3,5-diketotetrahydro-2H-pyran, is a chemical compound with the molecular formula C5H6O3. It is a cyclic diketone that is commonly used as a building block in organic synthesis and is also known for its potential applications in the pharmaceutical industry. It is used as a precursor in the synthesis of various pharmaceuticals and agrochemicals, as well as in the production of synthetic dyes and perfumes. Its structure and reactivity make it a valuable intermediate in the synthesis of a wide range of organic compounds. Additionally, PYRAN-3,5-DIONE has been studied for its potential as an antioxidant and anti-inflammatory agent, showing promising therapeutic properties.

InChI:InChI=1/C8H4Cl2N2O/c9-4-1-2-6-5(3-4)7(13)12-8(10)11-6/h1-3H,(H,11,12,13)

Upstream product

• 137840-76-7 methyl [(2-methylprop-2-en-1-yl)oxy]acetate 
• 10041-27-7 [(2-methylprop-2-en-1-yl)oxy]acetic acid 
• 61363-66-4 (2-oxopropoxy)acetic acid methyl ester 
• 67500-49-6 methyl 2-(prop-2-yn-1-yloxy)acetate 

Downstream Products

• 265320-48-7 9-(3-bromo-4-fluorophenyl)-2,3,5,9-tetrahydro-4H-pyrano[3,4-b]thieno[2,3-e]pyridin-8(7H)-one 1,1-dioxide 
• 265321-19-5 8-benzyl-5-(3-bromo-4-fluorophenyl)-5,8,9,10-tetrahydro-1H-pyrano[3,4-b][1,7]naphthyridine-4,6(3H,7H)-dione 
• 1403864-09-4 benzyl N-(5-hydroxyoxan-3-yl)carbamate 

Relevant articles and documents

Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: Design, synthesis, and protein-ligand X-ray studies

The design, synthesis, and biological evaluation of a series of HIV-1 protease inhibitors incorporating stereochemically defined fused tricyclic P2 ligands are described. Various substituent effects were investigated to maximize the ligand-binding site interactions in the protease active site. Inhibitors 16a and 16f showed excellent enzyme inhibitory and antiviral activity, although the incorporation of sulfone functionality resulted in a decrease in potency. Both inhibitors 16a and 16f maintained activity against a panel of multidrug resistant HIV-1 variants. A high-resolution X-ray crystal structure of 16a-bound HIV-1 protease revealed important molecular insights into the ligand-binding site interactions, which may account for the inhibitor's potent antiviral activity and excellent resistance profiles.

Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2, 6-dioxa-4-azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener

Structure-activity relationships were investigated on the tricyclic dihydropyridine (DHP) KATP openers 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H- 2,6-dioxa-4-azacyclopenta[b]naphthalene-1,8-dione (6) and 10-(3-bromo-4- fluorophenyl)-9,10-dihydro-1H,8H-2,7-dioxa-9-azaanthracene-4,5-dione (65). Substitution off the core of the DHP, absolute stereochemistry, and aromatic substitution were evaluated for KATP channel activity using Ltk- cells stably transfected with the Kir6.2/SUR2B exon 17- splice variant and in an electrically stimulated pig bladder strip assay. A select group of compounds was evaluated for in vitro inhibition of spontaneous bladder contractions. Several compounds were found to have the unique characteristic of partial efficacy in both the cell-based and electrically stimulated bladder strip assays but full efficacy in inhibiting spontaneous bladder strip contractions. For compound 23b, this profile was mirrored in vivo where it was fully efficacious in inhibiting spontaneous myogenic bladder contractions but only partially able to reduce neurogenically mediated reflex bladder contractions.

Pyrano, piperidino, and thiopyrano compounds and methods of use

The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.